# Primary Malignant Melanoma of the Oropharynx: A Rare Case of a Tonsillar Melanotic Lesion

**Authors:** Mazin J Albaldawy, Tamer Ebaied, Humaid O Al Shamsi, Ashraf Alkinain, Rahil U Faruk Abbu

PMC · DOI: 10.7759/cureus.82637 · 2025-04-20

## TL;DR

A rare case of primary oropharyngeal melanoma in a young woman is presented, highlighting the challenges in diagnosis and treatment of this aggressive cancer.

## Contribution

This paper contributes a detailed case report of a rare tonsillar melanoma with amelanotic presentation and treatment using immunotherapy and radiation.

## Key findings

- A 33-year-old patient presented with a pigmented tonsillar mass confirmed as amelanotic malignant melanoma.
- The patient was successfully treated with neoadjuvant pembrolizumab followed by radiation therapy.
- The case underscores the importance of multidisciplinary approaches in managing rare oral melanomas.

## Abstract

Oral malignant melanoma (OMM) is a rare and aggressive malignancy arising from melanocytes in the oral mucosa. We present the case of a 33-year-old Ethiopian female who arrived at the ED with hematemesis, active oral bleeding, and a sensation of suffocation. On examination, a darkly pigmented, ulcerated mass was identified arising from the left posterior tonsillar pillar. Emergency surgery was performed to control the bleeding, and subsequent histopathological analysis confirmed a diagnosis of amelanotic malignant melanoma, supported by immunohistochemical positivity for S100, HMB45, Melan-A, and P16. Advanced imaging with PET-CT and MRI demonstrated a localized tumor without evidence of lymph node involvement or distant metastasis. The patient was treated with neoadjuvant immunotherapy using pembrolizumab, followed by curative-intent radiation therapy targeting high-risk mucosal regions and bilateral cervical nodes. She tolerated the treatment well, though she experienced radiation-induced mucositis, dermatitis, and weight loss. Immunotherapy was resumed post-radiation, and the patient has since completed ten cycles without significant immune-related adverse events. The rarity of OMM and its aggressive clinical behavior underscore the need for heightened clinical suspicion for pigmented or ulcerated oral lesions. This case illustrates the diagnostic and therapeutic complexities of primary oropharyngeal melanoma, especially in the context of amelanotic presentation. It emphasizes the importance of prompt multidisciplinary evaluation, integration of advanced imaging modalities, immunohistochemical profiling, and emerging immunotherapeutic strategies to improve patient outcomes.

## Linked entities

- **Proteins:** S100A1 (S100 calcium binding protein A1), PMEL (premelanosome protein), CDKN2A (cyclin dependent kinase inhibitor 2A)
- **Diseases:** malignant melanoma (MONDO:0005105), mucositis (MONDO:0020579), dermatitis (MONDO:0002406)

## Full-text entities

- **Genes:** CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, S100A1 (S100 calcium binding protein A1) [NCBI Gene 6271] {aka S100, S100-alpha, S100A}, MLANA (melan-A) [NCBI Gene 2315] {aka MART-1, MART1}
- **Diseases:** mucositis (MESH:D052016), weight loss (MESH:D015431), oropharyngeal melanoma (MESH:D009959), pigmented or ulcerated oral lesions (MESH:D019226), Oral malignant melanoma (MESH:D008545), malignancy (MESH:D009369), hematemesis (MESH:D006396), Tonsillar Melanotic Lesion (MESH:D014067), dermatitis (MESH:D003872), amelanotic malignant melanoma (MESH:D018328), bleeding (MESH:D006470)
- **Chemicals:** pembrolizumab (MESH:C582435)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12091941/full.md

---
Source: https://tomesphere.com/paper/PMC12091941